Rafael Holdings Inc. Class B Common Stock (RFL)
NYSE NYSE Primary 
Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
Rafael NYSE: RFL reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026.
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out.
Oil prices fall as Hurricane Rafael expected to start weakening
Oil prices fell slightly on Friday as the risk that a hurricane in the Gulf of Mexico will affect U.S. oil and gas output declined while the market continues to weigh how President-elect Donald Trump's policies might affect supplies.
